Periostin (POSTN), a secreted homodimeric protein that binds integrins v3, v5 and 64, was originally found to be expressed in fetal tissues and in the adult upon injury particularly bone fractures due to its role in remodelling and repair. Recently it was found to be over-expressed in human breast cancer and a variety of other tumour types including head and neck squamous cell carcinoma, where its overexpression correlates with increased tumour invasion. Progress in studying its functional role in tumour pathogenesis has been hampered by the paucity of antibodies for its specific and sensitive detection. It has proven very difficult to obtain monoclonal antibodies (mAbs) against this highly conserved protein but we report here that combining infection of mice with lactate dehydrogenase elevating virus (LDV), a B cell activating arterivirus, with conjugation of human POSTN to ovalbumin as an immunogenic carrier, enabled us to develop 6 mAbs recognizing both human and mouse POSTN and inhibiting its binding to v3 
Immunohistochemistry using mAb MPC5B4 indicates that POSTN expression in breast tumour cells is a strong prognostic indicator, along with tumour size, lymph node, and HER2 status.
Introduction
POSTN, originally known as osteoblast-specific factor-2, is a 90kDa secreted glycoprotein that becomes incorporated into the extracellular matrix (ECM) (1) . It has an N-terminal signal sequence, followed by a 55 amino acid Emilin (EMI) domain and four 130 amino acid FAS1 homology domains (2) . The FAS1 domains have homology to the insect axon guidance protein, FAS1 (3) , and are cell adhesion modules that exhibit a novel seven-stranded -wedge with multiple -helical folds.
POSTN binds integrins v3, v5 and 64 leading to activation of the Akt/Protein kinase B (PKB) and Focal adhesion kinase (FAK) signalling pathways and promotion of cell survival, angiogenesis and resistance to hypoxia-induced apoptosis (4) . It also binds to a number of ECM proteins, dependent upon the cterminus, such as heparin, fibronectin, collagen V and tenascin C, thereby enhancing tumour cell invasiveness by affecting ECM fibrillogenesis (5) .
Integrins, the main receptors for POSTN, are a family of cell surface adhesion receptors composed of non-covalently associated  and  subunits. Integrin v3 is an adhesion receptor that drives tumour progression (6) and has been associated with poor outcome and a higher incidence of metastasis in epithelial cancers. It is expressed in breast, lung and pancreatic cancer stem cells that are highly resistant to receptor tyrosine kinase inhibitors and recruits KRAS and RalB to the plasma membrane leading to activation of NF-B sufficient for tumour initiation, anchorage independence, self-renewal and drug resistance (7) . v3 is also required downstream of hormonal signalling and TGF2 to regulate mammary stem cell number and alveolar development during early pregnancy (8) . It is also expressed on osteoclasts and implicated in osteoclast-mediated bone resorption and promoting bone metastases (9;10).
POSTN is expressed in a wide variety of fetal tissues (5) and in the adult upon myocardial, vascular and skeletal muscle injury and bone fractures due to its role in bone/dental remodelling and tissue repair following injury (11) . POSTN is a mesenchymal gene normally expressed by the stroma. Recently it was shown to be expressed by bronchial epithelial cells in response to Th2 cytokines IL-4 and IL-13 independently of TGF- and to represent a novel component of subepithelial fibrosis in bronchial asthma (12) . We originally found that POSTN RNA was over-expressed in malignant breast cancer cells and showed that expression in the cancer cells correlated with a poor outcome in estrogen receptor-positive breast cancers (13) .
Subsequently POSTN was reported to be expressed in other tumours including colon (14) , pancreatic (15) , ovarian (16;17) , non-small cell lung carcinomas (18) , head and neck cancer (19) and melanoma (20) . Serum POSTN levels rise upon metastasis and its expression is markedly increased at the invading edge of thyroid, colon and lung cancers (21) suggesting an involvement in tumour spread. Recently, a mechanism linking POSTN expression and breast tumour progression was proposed based on the observation that POSTN is essential for cancer stem cell maintenance in metastatic niches through activation of the Wnt pathway (22) .
Additionally, POSTN increases angiogenesis and lymphangiogenesis by upregulating vascular endothelial growth factor receptor-2 (VEGFR-2) (23) and promotes epithelial-mesenchymal transition (EMT) and invasion through activating lysol oxidase (LOX) (24) . POSTN also has the potential to impair anti-tumour immune responses by attracting M2 monocytes/ macrophages to the tumour niche as recently observed in experimental glioblastoma multiforme (25) .
These data suggest that inhibiting the effects of POSTN could have a place in antitumour therapies. Our approach towards this aim has been to develop inhibitory mAbs against POSTN, a product of not only breast cancer cells themselves but also of the related stroma. Here we report the production of a panel of highly specific mouse anti-human mAbs that inhibit POSTN binding to integrin v3 and block POSTN-dependent migration of human endothelial colony forming cells. We further report that immunohistochemistry (IHC) analyses indicate that POSTN expression in breast cancer cells is a strong prognostic indicator along with tumour size, lymph node, and HER2 status.
Materials and Methods

Cell Culture and Transfections
Hs578T and HEK293T cells were obtained from the American Type Culture Collection (ATCC) and A375P6 cells were provided by Prof. J. F. Marshall (Barts Cancer Institute, London, UK). Hs578T cells expressing lower levels of POSTN were generated by lentiviral mediated RNA silencing using GIPZ V3LHS_363447 and 363450 human POSTN lentiviral shRNAmirs (GE Healthcare Open Biosystems).
Human endothelial colony forming cells (ECFC) were isolated from human umbilical cord blood, collected in sterile pyrogen-free bags (Green Cross, Yongin, Korea) containing anticoagulant. Written informed consent was obtained from all donors and the study was approved by the Institutional Review Board of Pusan National University Hospital. Mononuclear cells were isolated with Histopaque-1077 (SigmaAldrich, Switzerland) as described previously (26) . ECFC were seeded on 0.1% gelatin coated culture dishes (Sigma-Aldrich) and maintained in Endothelial Growth Medium -2 Bullet Kit (EGM-2 bullet kit, Lonza AG, Switzerland). After four days nonadherent cells were removed and the adherent cells trypsinized and re-plated at a density of 1×10 6 per well until day 7 (27) .
Immunization and generation of hybridomas
CBA/ca female mice were infected with LDV, a single stranded positive sense RNA enveloped arterivirus with B cell activation properties (28;29) , by intra-peritoneal injection of infected plasma. One day later they were immunized in the footpads with 10g human POSTN (Biovender Laboratory Medicine, Inc., Palackeho, Czech Republic) conjugated to ovalbumin (OVA) and emulsified in Gerbu 100 adjuvant (GERBU Biotechnik, Heidelberg, Germany). For conjugation to OVA, POSTN was first polymerized for 1 hour with 100mM N-(3-dimethylamino propyl)-N'-ethylcarbodiimide in the presence of 10mM N-hydroxysulfosuccinimide in 0.1M MES buffer pH4.8. After dialysis against 0.1M acetate buffer pH5.8, polymerized POSTN was conjugated to glutaraldehyde activated OVA (30) . Mice were boosted 3 times at 2 week intervals, followed by an intravenous injection of 5µg POSTN 4 days before spleen cell fusion to SP2 plasmacytoma cells. Six anti-POSTN mAbs were selected. M444 (IgM) and M465 (IgG1) anti-2, 4, 6-trinitrophenyl (TNP) mAbs were used as controls.
Antibodies were screened by ELISA on MAXISORP Nunc Immunoplates (Roskilde, Denmark) coated with 200ng/ml human or mouse POSTN (R&D Systems, MN) and detected using HRP-conjugated goat anti-mouse IgG (BD Bioscience, NJ).
Reduction and alkylation was performed by incubating POSTN with DTT (18mM) for 1 hour, followed by iodoacetamide (150mM).
Integrin inhibition
Integrin v3-coated (200ng/ml) ELISA plates were incubated with a mixture of unlabelled (50g/ml) and biotinylated (0.5g/ml) human POSTN for 2 hours with and without anti-POSTN antibodies. After washing, streptavidin-horseradish peroxidase (HRP) was added for 2 hours. MAb dilutions were used to calculate IC50.
Mapping the Antibody Binding Sites
In vitro protein synthesis was performed using the TNT Quick Coupled Transcription/ Translation System (Promega, WI) to generate fragments of the POSTN protein.
This system couples RNA transcription from a DNA template with translation of the transcribed RNA in a single reaction that utilises rabbit reticulocyte lysate. 50l reactions assembled according to the manufacturer's guidelines were incubated at 37°C for 90 minutes and the products used for western blotting or ELISA.
Sixteen-mer POSTN peptides were used to coat ELISA plates at 10g/ml in 50mM glycine buffer pH9. 5 
Adhesion Assay
To prepare POSTN coated plates, 50l of 10g/ml of POSTN diluted in TBS (10- (D1) at 4°C overnight, followed by blocking with PBS containing 0.2% BSA for 1 hour at 37°C. To assess mAb inhibitory activity, plates pre-coated with recombinant POSTN or its FAS1-1 (D1) domain were pre-incubated with 1g/ml MPB4B1(IgM) or MPC5B4(IgG1) at 37°C for 30 minutes. Cells were trypsinized and suspended in the culture media at 2 × 10 5 cells/ml, and 0.1 ml of the cell suspension was then added to each well of the plate. Analysis of cell attachment was performed as follows.
After incubation for 1 hour at 37°C, unattached cells were removed by rinsing twice with PBS and the number of attached cells determined by counting under microscopy at 100x magnification after staining with hematoxylin and eosin.
Cell Migration Assay
Cell migration assay for ECFC was carried out in disposable 96-well chemotaxis chambers (Neuro Probe, Inc., Gaithersburg, MD). ECFC were harvested with 0.05% trypsin containing 0.02% EDTA, washed once, and suspended in EBM-2 at a concentration of 1x10 5 To investigate the involvement of integrin αvβ3 in POSTN or FAS1-1 domainstimulated migration, ECFC were pre-incubated with 3 different POSTN peptides (10g/ml) corresponding to amino acids 136-151, 140-150 and 112-127 of POSTN respectively, at 37°C for 30 minutes. ECFC were then loaded into the upper chamber pre-coated with rat-tail collagen, and migration determined after incubation with VEGF (10ng/ml), Vitronectin (10g/ml; PeproTech, Inc., NJ), recombinant POSTN (10g/ml) or FAS1 -1 domain (D1) of POSTN (10g/ml) for 12 hours. significant cross-reactivity with the mouse protein, demonstrating that the vaccination procedure had breached immune self-tolerance. Important differences in the avidities of these mAbs were observed with half maximal binding concentrations ranging from ±1ng/ml for MPC5B4 to >10g/ml for MPB4B1. Moreover, crossreactivity with mouse POSTN showed significant differences, indicating that these antibodies were derived from distinct B cells.
Immunohistochemistry and tissue microarray analysis
Since TGF1 is highly homologous to POSTN, we also tested whether these anti-POSTN antibodies will cross-react to TGF1 by ELISA. We found that MPB4B1, MPC1C3, MPC4B12, MPC5B4 and MPD9D5 showed no reactivity whereas MPC7A9 did exhibit a low level of cross reactivity. Since MPC7A9 is an IgM antibody that has a unique property of binding to Protein A, the low level of interaction of MPC7A9 with TGF1 is likely to be due to a non-specific stickiness of this IgM antibody (data not shown).
Inhibition studies using anti-POSTN antibodies
The inhibitory activity of these six mAbs was first tested by evaluating their influence on binding of human POSTN to integrin v3-coated ELISA plates. IC50 for inhibiting POSTN (5g/ml) binding ranged from 1 to 30g/ml for the mAbs illustrated in Fig.2A . We also tested the ability of these six mAbs to inhibit POSTN binding to integrin v5-coated ELISA plates. The results were very similar but much less reproducible (data not shown).
The inhibitory activity was also tested by inhibition of adherence of A375P6 melanoma cells to POSTN-coated plastic plates. A375P6 cells express integrins 51, v3, v5, v6 and v8 (32) which can be non-specifically activated by preparation in a Manganese containing buffer. The ability of these cells to adhere to POSTN-coated plates was compared to BSA coated plates. We then determined if our anti-POSTN mAbs would block the adherence of A375P6 cells to POSTN.
MPB4B1 and MPC7A9 (both IgM) were the most inhibitory but MPC5B4 (IgG1) and MPD9D5 (IgG2b) also significantly hindered cell adhesion (Fig.2B ). MPC1C3 and MPC4B12 which inhibited POSTN binding to v3 were inactive in this assay.
MPB4B1 also significantly inhibited adhesion of ECFC to POSTN or its FAS1-1 domain but not to collagen (Fig. 2C) . Vitronectin, an adhesive protein, that is known to bind a variety of integrins including v3, v5, v6 (33) also induces adhesion of A375P6 melanoma cells. This was not inhibited by MPB4B1 (Fig. 2D) , demonstrating that the inhibitory activity of this antibody was targetted against POSTN.
Identification of POSTN sequences recognized by the antibodies
As our goal was to develop mAbs that were highly specific for western blotting and IHC and use them to unmask POSTN sequences required for its interaction with integrins, we tested whether they would react with linearized POSTN in western blots. MPC5B4 was the only mAb that detected POSTN expression in lysates of Hs578T human breast cancer cells, a cell line previously shown to express POSTN (20) . It detected a 90kDa band which was lost when POSTN was silenced by RNA interference (Fig. 3A) ; POSTN expression and its silencing were confirmed at the RNA level (Fig. 3B) . This attested to the specificity of MPC5B4 and also indicated that it recognized a linear epitope.
To determine the site recognised by MPC5B4, POSTN was divided into three fragments (F1, F2 and F3; Fig. 3C ) which were cloned into pBlueScript SK+ and in vitro translated using the TNT T7 Quick Coupled Transcription/Translation System. The products of the three POSTN fragments as well as the full length molecule were immunoblotted (Fig. 3D) . MPC5B4 recognised only F1 and FL indicating that the epitope was located within the first 260 amino acids. To further refine the epitope location, overlapping fragments (F4 and F5; Fig. 3C ) corresponding to F1 were generated and the in vitro translated products tested by ELISA (Fig. 3E) . Fragments F1 and F5 were recognized by MPC5B4 but not F4, thereby localising the epitope to aa 94-176.
16-mer peptides with 8aa overlaps covering aa 94-176 were synthesized and tested for MPC5B4 binding by ELISA. Only peptide 136-151 (APSNEAWDNLDSDIRR) was positive (Fig. 4A) . To further refine the epitope, we performed competition experiments to avoid epitope masking or poor adsorption of these small peptides to ELISA plates. MPC5B4 was incubated overnight with competing peptides to saturate its binding sites before transfer to POSTN-coated plates. Peptide 136-151 completely inhibited binding to POSTN (Fig. 4A&B) , indicating that this was the only sequence recognized by this antibody on POSTN. Further trimming of the competing peptides showed that peptide 140-150 (EAWDNLDSDIR) was still able to block MPC5B4 binding to POSTN whereas 142-151 (WDNLDSDIRR) was not inhibitory (Fig. 4B&C) . This indicated that the epitope for MPC5B4 is located within aa140-150 and corresponds to the POSTN region involved in its interaction with integrin v3. Interestingly binding of the five other mAbs MPB4B1, MPC1C3, MPC4B12, MPC7A9 and MPD9D5 to POSTN was also inhibited by peptide 136-151 but only MPC5B4 and MPB4B1 reacted with peptide 140-150 (Fig.4C ). MPC1C3
and MPC4B12 also interacted slightly with peptide 128-143 suggesting that aa136-143 were likely to be part of their epitope. Interestingly these two mAbs did not significantly block adherence of A375P6 cells to POSTN (Fig. 2B) . As a control, we tested OC20, the antibody described by Orecchia et al which binds POSTN within the FAS1-2 domain (34); none of the peptides were able to compete with the interaction between OC20 and POSTN (data not shown).
Inhibition of ECFC migration
Recombinant POSTN has been shown to promote migration of ECFC via the FAS1- 
Clinical significance of POSTN expression in breast cancer
To evaluate whether mAb MPC5B4 can be used to identify POSTN expression in human tumour tissue, we performed IHC analysis on tissue microarrays of normal breast and breast cancer tissue. POSTN was, as expected, consistently expressed in the stromal compartment of normal and tumour samples (Fig. 6 ). We also observed variable expression of POSTN in tumour epithelial cells and so subsequent observations relate to POSTN expression in this epithelial cell compartment.
We first analysed expression of POSTN in a small cohort comprising matched normal breast, pre-invasive lesions and invasive tumours (cohort 1) to qualitatively examine changes in POSTN expression during tumour development. POSTN staining was consistently negative in normal epithelial cells (Fig. 6A) Fig. 2 ). Comparing matched in situ and invasive lesions, POSTN expression was unchanged in 7/17 (41%) cases (6 were negative in both components) and yet was increased in the invasive component relative to the in situ component in 10/17 (59%) cases. Although this is a small cohort, this pattern of expression of POSTN is intriguing and implies that epithelial cell-specific expression of POSTN might be dynamically regulated as tumour cells come into direct contact with the stromal microenvironment.
Next we examined POSTN expression in 449 invasive breast carcinomas with long term follow up (cohort 2). We found that the epithelial cell compartment of 43.3% invasive breast tumours expressed POSTN to moderate-strong levels (Fig. 6C) .
Interestingly, in cases with heterogeneous expression levels the strongest expression was often seen in cells at the tumour-stroma interface (Fig. 6D) . Chi square analysis showed associations between tumour cell POSTN expression and HER2 status (P=0.0004), histological grade (P=0.0021), patient age (P=0.0046), lymphovascular invasion (P=0.002), central scarring/fibrosis (P=0.0084) and molecular subgroup (P=0.0081) (Supplementary Fig. 3 ). POSTN staining intensity was inversely correlated with overall survival (P=0.0013, 25 years post-diagnosis) ( Supplementary Fig. 4 ). We also analysed the prognostic significance of tumour cell POSTN in a multivariate cox proportional hazards model, and found that after accounting for lymph node status and tumour size, POSTN staining was the next most significant prognostic indicator (P=0.0321; Fig. 6E ).
Discussion
Here we report that a combination of POSTN coupled to OVA as an immunogen and mice infected with LDV virus has enabled production of highly specific anti-POSTN mAbs that inhibit the interaction between POSTN and v3 integrin and identify the Differences were however noted between these antibodies when using smaller peptides and also in the extent of reactivity with the mouse protein indicating that they were not derived from the same B cell precursor. Several of these antibodies completely inhibited POSTN binding to v3 integrin suggesting that the 136-151 POSTN sequence could be targeted for functional inhibition.
The development of highly specific antibodies was important because our original study demonstrating POSTN expression within the cancer cells had been undertaken with a commercial rabbit polyclonal antibody which detected other bands in addition to POSTN on western blots (unpublished data). This anti-POSTN antibody was subsequently used to demonstrate a positive correlation between POSTN expression, hormonal receptors, tumour size and unfavourable outcome in a panel of 189 breast tumour samples (38) . The IHC analysis presented here, using the highly specific MPC5B4 mAb, showed that POSTN expression in the cancer cells was a significant prognostic indicator in both univariate and multivariate analyses.
After accounting for lymph node status and tumour size, POSTN expression was found to be more prognostic than HER2 status and grade. Our study also suggests that POSTN expression increases upon tumour progression but a much larger study involving more cases is required to reach statistical significance since our data set comprised only 23 cases. However, this hypothesis is in accordance with the recent report linking POSTN expression and breast tumour progression showing that POSTN is essential for cancer stem cell maintenance in metastatic niches through activation of the Wnt pathway (22) .
This study has identified mAbs that can block the interaction between POSTN and v3. We have found that all six mAbs presented here recognize epitopes in the 16aa (APSNEAWDNLDSDIRR) located at position 136-151 within the FAS1-1 domain. Moreover the APSNEAWDNLDSDIRR peptide is able to block POSTN dependent migration of ECFC. This is very surprising and not in accordance with the v3 and v5 interaction sites on igH3, a protein that is structurally homologous to POSTN. It has been found that both v3 and v5 interact with all 4 FAS1 domains within igH3 (39;40) . The interaction site comprises a tyrosine (Y) histidine (H) motif flanked by leucine and isoleucine residues which are all highly conserved within the FAS1 domains (KELANILKYHMVGRRVLY) (39;40) . POSTN contains two homologous YH motifs located within FAS1-2 and FAS1-4, neither of which is close to aa136-151. It is of course possible that POSTN and v3 do not interact at exactly the same site as igH3 and v3 but it is more likely that our mAbs perturb the binding site by steric hindrance or their accessibility given the size of the antibody molecule or the interaction perturbs the structure of the YH motifs. In any case, our results identify a novel APSNEAWDNLDSDIRR sequence that can be targetted for inhibiting POSTN function. It is interesting to note that vitronectin that is known to bind a variety of integrins including v3, v5, v6 (33) also does not contain a YH motif or a sequence with significant homology to APSNEAWDNLDSDIRR even though vitronectin mediated migration of ECFC was also specifically inhibited by the FAS1-1 aa 136-151 peptide.
This conundrum was also raised by the inhibition of integrin mediated cell adhesion. 
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